SILENCE THERAP. SP.ADR/1 (XRP2) — Strategic Asset Allocation Index
SILENCE THERAP. SP.ADR/1 (XRP2) has a Strategic Asset Allocation Index of 0.3% as of September 2024. Strategic assets (PP&E of €- plus long-term investments of €380.05K) total €380.05K, measured against net assets of €126.48 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check asset resilience ratio of SILENCE THERAP. SP.ADR/1 to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
SILENCE THERAP. SP.ADR/1 Strategic Asset Allocation Index (2021–2023)
This chart shows how SILENCE THERAP. SP.ADR/1's Strategic Asset Allocation Index has evolved across 3 annual periods from 2021 to 2023. As of September 2024, the index stands at 0.3%, representing strategic assets of €380.05K against net assets of €126.48 Million EUR. See XRP2 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for SILENCE THERAP. SP.ADR/1 (2021–2023)
The table below presents the year-by-year Strategic Asset Allocation Index for SILENCE THERAP. SP.ADR/1 from 2021 to 2023, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see XRP2 market cap overview.
| Year | SAAI | Strategic Assets (EUR) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2023 | 1.6% | €361.79K | €- | €361.79K | €21.99 Million | ▲ +0.4 pp |
| 2022 | 1.3% | €343.70K | €- | €343.70K | €26.71 Million | ▼ -2.2 pp |
| 2021 | 3.5% | €406.24K | €- | €406.24K | €11.51 Million | — |